Introduction 83
Knee osteoarthritis (OA) is the most common joint disease in middle-aged and 84 elderly, causing serious morbidity and large socio-economic impact (1, 2) . Since no 85 definitive treatment options other than joint replacement surgery in end stage OA are 86 available, research focuses on development of disease modifying osteoarthritis drugs 87 (DMOADs) which may be effective in early OA, for example by improving cartilage 88 biochemical composition (3, 4) . 89
To non-invasively monitor effectiveness of these novel interventions on 90 cartilage biochemical composition, imaging techniques are essential. Therefore, 91 quantitative imaging assessing important cartilage composites i.e. sulphated 92 glycosaminoglycan (sGAG) and collagen, became of interest (5) . 93
Most imaging techniques applied in clinical research are magnetic resonance 94 imaging (MRI) based, e.g. delayed gadolinium-enhanced MRI of cartilage 95 (dGEMRIC) for analyzing sGAG content (6) and T2-mapping for analyzing collagen 96 5 content (7) . Computed tomography (CT) based techniques have also been developed, 97 but are mainly applied in in vitro or animal research. Examples are: equilibrium 98 partitioning of an ionic contrast agent using micro-CT (EPIC-μCT) and μCT 99 arthrography to estimate sGAG content (8) (9) (10) (11) (12) (13) (14) . 100
Recently, a clinically applicable protocol for CT arthrography (CTa) was 101 introduced as a potential alternative technique to MRI based estimate of cartilage 102 biochemical composition (15) . Outcomes of ex vivo CTa applied in human cadaveric 103 knee joints were shown to strongly correlate with cartilage sGAG content based on 104 the inverse relation between the negatively charged sGAG and the ionic contrast agent 105 used, similar to the working mechanism of dGEMRIC. (15) . However, outcomes of 106 CTa were also dependent on integrity of the collagen network of cartilage, which 107 influences the speed of contrast influx into cartilage (15) . Although CTa was already 108 applied in vivo by comparing its outcomes to dGEMRIC and cartilage morphology 109 observed during arthroscopy (16, 17) , these studies did not assess the correlation 110 between CTa and reference standards for cartilage biochemical composition and were 111 not performed in knee OA patients which constitute an important target population for 112 quantitative imaging techniques for cartilage composition. 113
The aim of this study was to assess the correlation between in vivo CTa in 114 human knees with OA and ex vivo reference standards for sGAG and collagen 115 content. 116 117
Methods 118
Study design and participants 119 6 For this prospective observational study, conducted between October 2012 and 120 December 2013, all consecutive patients scheduled for total knee replacement (TKR) 121 at our institution were approached. 122
The inclusion criteria were: age ≥ 18 years and radiographic knee OA with 123 asymmetric distribution and a maximum of grade 1-2 (doubtful or definite osteophyte 124 formation without definite joint space narrowing) according to the Kellgren & 125 Lawrence (KL) grading system (18) in the least affected tibiofemoral compartment. We 126 chose to include only these patients to be sure that we captured a relatively wide range 127 of cartilage quality and therefore also sGAG content of the articular cartilage. 128 Exclusion criteria were: glomerular filtration rate < 60 ml/min, previous reactions to 129 CT contrast agent and co-morbidities in the ipsilateral lower extremity precluding 130 exercise after contrast administration. 131
We performed a power analysis in which we used the Fisher transformation 132 (19) to assess the number of measurements needed to establish a correlation coefficient 133 of at least 0.7 (considered a good correlation (20) ) with a predefined 95% confidence 134 interval width of 0.5 -0.9, and found that 25 measurements would be needed. Since 135 six measurements are performed per participant, three participants would be enough 136 for our study. Because we considered this number very low, we decided to include at 137 least 10 participants (60 measurements for the correlation analyses) until the end date 138 of the study (December 2013). 139
The study was approved by the institutional review board of our institution 140 (MEC-2012-218) and written informed consent was obtained from all participants. 141 142 Acquisition of CT arthrography 143 7 CTa was performed four weeks before TKR. This time window was chosen to 144 allow detection of infection caused by the intra-articular injection well before surgery. 145
Patients were positioned in a supine position and after disinfection, 15 ml 30% 146 ioxaglate (Hexabrix 320, Mallinckrodt, Hazelwood, USA) and 70% 1% phosphate 147 buffered saline (PBS) solution was injected intra-articularly using a 21 gauge needle 148 (15) and a superolateral approach (21) . We first aspirated synovial fluid from the knee in 149 order to confirm that the needle was positioned in the knee joint and to ensure that we 150 could inject the 15 ml of contrast dilution while minimizing further dilution due to 151 extensive joint effusion. To promote contrast distribution throughout the joint, 152 participants actively exercised their knee for two minutes over the full possible range 153 of motion immediately after the injection. 154
Ten minutes post-injection, CT in the axial plane was acquired using a dual-155 source multidetector spiral CT scanner (SOMATOM Definition Flash, Siemens 156
Healthcare AG, Germany). We used a tube voltage of 80 kV, units of current of 3140 157 mAs, pitch of 0.35 and collimation of 32 x 0.6 mm (15) . Scan time was approximately 158 30 seconds. These parameters resulted in an effective radiation dose of 0.4 millisievert 159 (mSv) and an effective skin dose of 120 milligray (mGy) which is well below the 160 threshold of 1000 mGy above which deterministic effects on the skin are expected (22) . We used EPIC-μCT as reference standard for cartilage sGAG content since its 183 outcomes have a good correlation with cartilage sGAG content (8, 9, 14) . Similar to CTa, 184 EPIC-μCT provides information on sGAG distribution of cartilage within the entire 185 cartilage volume, allowing analysis of articular cartilage regions exactly matching the 186 cartilage ROIs analyzed with CTa. 187
Between 30 minutes and 1 hour after surgery, all specimens were removed 188 from the saline and incubated in ioxaglate solution for 24 hours at room temperature 189 (24) (25) (26) . A 20% ioxaglate with 80% PBS 1% solution was used since this results in 190 optimal cartilage segmentation at the air/cartilage and bone/cartilage interfaces (15) . 
Analysis of EPIC-μCT 203
To enable comparison of corresponding cartilage regions, EPIC-μCT datasets 204 were registered to CTa datasets with Multimodality Image Registration using 205 Information Theory (MIRIT, University of Leuven) (27) . This automated registration 206 algorithm uses a rigid transformation model (translations and rotations) and uses 207 mutual information as a similarity measure for the registration of the μCT datasets to 208 the CT datasets. Next, using CT Analyser software, datasets were segmented into 209 binary datasets using a previously determined fixed attenuation threshold (25 gray 210 values for air and 120 gray values for subchondral bone) (15) . In the segmented μCT 211 datasets, cartilage ROIs corresponding with ROIs of CTa were drawn and mean X-ray 212 attenuation was calculated. The other half of each explant was used to quantify collagen content based on 236 the hydroxyproline content according to Bank et al. (29) . Samples were digested with 237 alpha-chymotrypsin followed by a papain solution and digests were hydrolyzed with 238 equal volumes 12M HCl at 95 ºC overnight. Samples were then dried and re-dissolved 239 in water. Hydroxyproline content was measured using a colorimetric method with 240 chloramine-T and dimethylaminobenzaldehyde as reagents and hydroxyproline as 241 11 standerd (Merck, Darmstadt, Germany) at extinction 570 nm. Values of degraded and 242 intact collagen content were summed, resulting in total collagen content per explant. 243
Next, for each ROI four to eight explants were used to calculate the mean 244 sGAG and collagen content by averaging the content of the explants taken from that 245 specific ROI. The mean sGAG and the mean collagen content of a specific cartilage 246 ROI could then be correlated with the mean CT and μCT attenuation in the matching 247
ROI. 248 249

Statistical analysis 250
To assess the correlation between CTa and reference tests (EPIC-μCT, sGAG 251 content and collagen content), a four-dimensional multivariate mixed-effects model 252 was applied. In this model, it is assumed that the CTa and the reference tests are 253 multivariately normally distributed (i.e. Y~N 4 (μ,Σ), where Y = (CTa, EPIC-μCT, 254 sGAG content, collagen content); μ and Σ are the mean vector (i.e. μ = (μ 1 = CTa, μ 2 = 255 EPIC-μCT, μ 3 = sGAG content, μ 4 = collagen content)) and covariance matrix of these 256 variables, respectively. To take into account potential intrinsic correlation between 257 outcomes of different ROIs within one participant, a random intercept was included in 258 the model (e.g. μ 1,i.j. = β 1 + b 1,I ; i = 1, … , 11, j; j= 1, …, 62). 259
Pearson's correlation coefficients of CTa and each reference test were 260 extracted from the results of this model. For each Pearson's correlation coefficient the 261 95% credibility interval (95%CI) was calculated. To assess goodness-of-fit, we used 262 an omnibus posterior predictive check (PPC) (30) . We computed a Bayesian p-value 263
with extreme values of this p-value (e.g., < 0:05 or > 0:95) indicating a poor fit of the 264 model to the data (30) . 265
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To assess if the correlation coefficients calculated within the model were 266 significantly different, we calculated the contour probability of the correlations. For 267 these values, similar to the Bayesian p-value, extreme values, i.e. <0.05 or >0. 95, 268 indicate that there is a statistically significant difference between two correlation 269 coefficients (31) . 270
An additional univariate mixed-effects regression analysis was performed to 271 estimate the capability of in vivo CTa to predict outcomes of ex vivo EPIC-μCT (thus 272 sGAG content). In this analysis, we modeled EPIC-μCT outcomes based on CTa 273 measurements, using random effects to capture heterogeneity between patients, and 274 predicted the EPIC-μCT outcomes and their 95%CI for all cartilage regions. 275
All analyses were performed using a Bayesian approach with Markov chain 276
Monte Carlo (McMC) sampling using WinBugs (32) . 277
278
Results 279
Participants 280
Fourteen patients were included. Two participants were excluded because their 281 TKR was postponed after inclusion, in one participant ioxaglate was injected extra-282 articularly and four cartilage specimens (two weight-bearing cartilage specimens of 283 the medial tibial plateau, one posterior non-weight-bearing cartilage specimen of the 284 lateral femoral condyle and one weight-bearing cartilage specimen of the medial 285 femoral condyle) were severely damaged during surgery and were therefore excluded 286 from the analysis. Therefore, results are based on data of 11 participants (5 women 287 and 6 men, 7 left and 4 right knees). 288
The mean age with standard deviation was 64 ± 7 years and their mean body 289 mass index with standard deviation was 33 ± 6 kg/m 2 . The KL grades in the medial 290 13 tibiofemoral compartments were 3 or 4 in seven participants and 1 or 2 in four 291 participants. KL grades in the lateral tibiofemoral compartments were 1 or 2 in nine 292 participants and 3 in two participants. We did not observe any adverse reactions 293 related to the intra-articular contrast injections. 294 295
Correlation of CTa, EPIC-µCT and biochemical cartilage analyses 296
For the applied four-dimensional mixed-effects model, the Bayesian p-value of 297 the PPC was 0.52, which indicates that the model assumptions appear to be satisfied. 298
Mean CTa X-ray attenuation in all femoral and tibial cartilage ROIs correlated 299 well with attenuation of EPIC-μCT (r=0.76, 95%CI 0.64 to 0.85; Figure 2A ). When 300 each ROI was analyzed separately, the range of correlation coefficients between 301 outcomes of CTa and EPIC-μCT was 0.75 to 0.80. 302
The correlation between CTa and sGAG content measured using the DMMB 303 assay was moderate (r=-0.66, 95%CI -0.87 to -0.49; Figure 2B) . A range of -0.75 to -304 0.60 was observed for the correlation coefficients between X-ray attenuation of CTa 305 and sGAG content in all separate cartilage ROIs. 306
The correlation between outcomes of CTa and collagen content measured 307 using the hydroxyproline assay was also moderate (r=-0.56, 95%CI -0.70 to -0.36; 308 Figure 2C ). Here, a range of correlation coefficients from -0.56 to -0.51 was obtained 309 for each separate ROI. 310
Mean EPIC-μCT outcomes and sGAG content measured using the DMMB 311 assay correlated well (r=-0.81, 95%CI -0.87 to -0.69; Figure 2D ). The range of 312 correlation coefficients for each separate ROI was -0.82 to -0.75. 313
By calculating the p-values of the contour probability of the different 314 correlations we observed that the correlation between CTa and EPIC-μCT was 315 14 significantly different from the correlation between CTa and sGAG or collagen 316 content (contour probability > 0.99). The correlation between EPIC-μCT and sGAG 317 content was significantly different from the correlation between EPIC-μCT and 318 collagen content (contour probability = 0.002). The other correlation coefficients did 319 not differ significantly from each other. 320
The matched images of CTa, EPIC-μCT and histology (visual representation 321 of sGAG content using Safranin-O staining) representing cartilage with relatively 322 high and low sGAG content shown in Figure 3 confirmed the good correlation 323 between CTa and EPIC-μCT and cartilage sGAG content. 324
The additional univariate mixed-effects regression analysis to estimate the 325 capability of CTa to predict EPIC-μCT showed that the 95%CIs of the predicted 326 EPIC-μCT outcomes overlap with all of the observed outcomes of CTa, indicating 327 good predictive performance (Figure 4) . OA. This study was performed to assess the correlation between in vivo CTa in human 333 OA knees and ex vivo reference standards for sGAG and collagen content. 334
Our results show a good correlation between X-ray attenuation of CTa and EPIC-335 μCT, a good predictive performance of CTa for EPIC-μCT outcomes, and a somewhat 336 less pronounced correlation between CTa and cartilage sGAG content determined by 337 the DMMB assay. These results are in agreement with previous research showing a 338 good correlation between outcomes of CTa acquired in ex vivo human cadaveric knee 339 joints and EPIC-μCT (15) . The results are also consistent with several previous in vitro 340 studies examining the correlation between contrast-enhanced (micro)CT and the 341 sGAG content of articular cartilage (8, 9, 14) . Therefore, we believe that CTa X-ray 342 attenuation may be used as a quantitative estimate for sGAG content of articular 343 cartilage in future clinical OA research. 344
The difference in strength of correlation between CTa and sGAG content 345 measured using EPIC-μCT versus DMMB assay might be caused by the fact that the 346 attenuation of EPIC-μCT and cartilage sGAG content are well correlated, but not by a 347 linear relationship. This indicates that, although not fully specific, EPIC-μCT is good 348 reference test for cartilage sGAG content. Another explanation for the difference in 349 strength of correlation may be that the ROIs in CTa and EPIC-μCT were matched 350 exactly by image registration while the DMMB assay was limited to assessment of 351 sGAG content in representative cartilage explants that did not correspond exactly with 352 the cartilage volume of the imaging ROIs. We chose this approach since we 353 considered it to be reliable to analyze representative focal cartilage explants taken 354 from standardized locations out of the cartilage ROIs analyzed using CTa and EPIC-355 μCT. Since there were no large spatial differences in sGAG distribution within 356 cartilage ROIs in EPIC-μCT (data not shown), we are convinced that this did not 357 influence our results compared to analyzing total cartilage ROIs using the DMMB 358 assay. 359
An import remark with regard to the interpretation our results is the fact that 360 the observed good correlation between CTa and EPIC-μCT does not automatically 361 imply that both tests have equal or comparable diagnostic capacity. Calculation of 362 diagnostic performance statistics such as sensitivity, specificity, positive predictive 363 value and negative predictive value requires the availability of threshold values that 364 are indicative for disease (in our study OA). Although sGAG content is diminished in 365 16 OA, no threshold values exist for sGAG content in relation to diagnosis of OA. 366
Despite the absence of these analyses, but because of the moderate to strong 367 correlation between outcomes of CTa and cartilage sGAG content and the good 368 predictive performance of CTa for EPIC-μCT (thus sGAG) outcomes, we consider 369
CTa as a worthwhile quantitative estimator of cartilage sGAG content in future 370 clinical research. 371
We found a moderate correlation between outcomes of CTa and collagen 372 content of cartilage measured using the hydroxyproline assay. This result could 373 potentially be explained by a strong relation between collagen and sGAG content of 374 cartilage and a concomitant loss of sGAG and collagen in the OA process. Cartilage 375 sGAG and collagen content were, however, only weakly correlated in our study 376 (r=0.40, data not shown). This indicates that, in addition to sGAG content, the 377 integrity of the collagen network also influences contrast influx into cartilage as 378 suggested in previous ex vivo research (15) . It is important to note that in CTa, there is 379 no equilibrium between cartilage sGAG content and the contrast agent because CTa 380 images are acquired already 10 minutes after contrast administration. This is unlike 381 EPIC-μCT in which cartilage is incubated in contrast agent for 24 hours (8, 9, 14) . 382 Therefore, measurements from non-equilibrium CTa are also influenced by other 383 factors than sGAG content alone (24) (25) (26) . In particular, the collagen network of the 384 extracellular matrix of the cartilage, which determines the permeability of the 385 cartilage, influences the diffusion rate of contrast agent into the cartilage besides its 386 sGAG content (33, 34) . Contrast diffusion goes slowly in healthy cartilage, in which an 387 intact collagen network and densely packed collagen parallel to the cartilage surface 388 result a relative low permeability of the cartilage (35, 36) . When the collagen network is 389 impaired, e.g. in case of loss of collagen content, cartilage permeability increases, 390 17 resulting in higher diffusion rate of contrast into the cartilage. can be acquired already ten minutes after contrast administration, while the delay 400 between intravenous contrast administration in knee dGEMRIC is at least 1.5 hours 401 (37) . This makes CTa more patient friendly and clinically feasible than MRI. 402
Moreover, in the generally middle-aged or elderly OA population, the relative long 403 acquisition time of MRI compared to CT (minutes versus seconds) and the number of 404 patients with possible contra-indication for MRI (for example non MRI compatible 405 implants) may favor CTa as an alternative to MRI in clinical OA research (38) . CTa 406 might also be applicable as imaging biomarker for cartilage biochemical composition 407 in large cohort studies since it is relatively cheap and widely available (39) . 408
Potential limitations of CTa include concerns of ionizing radiation. The 409 effective radiation dose used for CTa as presented in this paper (0.4 mSv) is four times 410 higher than a regular CT of the knee (40) . However, it has been shown that CTa acquired 411 using only 10% of this dose also has a good correlation with cartilage sGAG content ex 412 vivo in cadaveric knees (41) . Besides, active knee flexion and extension may be 413 impossible for the full range of motion for OA patients, resulting in variations in contrast 414 concentration across the knee joint. Recent research by Silvast et al., however, shows that 415 18 differences in contrast concentration do not influence the speed of contrast influx into 416 cartilage and would therefore not influence the reliability of CTa outcomes (42) . Finally, 417
although not observed in our study and also not reported in other studies applying 418
CTa in vivo in humans (16, 17) , the intra-articular injection introduces the risk of 419 infection and increases the risk of knee pain after injection. It may be worthwhile to 420 perform fluoroscopic-guided intra-articular injections in future research with CTa 421 since this may overcome the problem of extra-articular contrast agent deposition, 422 which happened in one of our study participants, however against increased costs and 423 logistic complexity of the procedure. 424
Based on our results and despite the potential drawbacks we propose that CTa 425 may be applicable in future clinical OA research as an estimate for cartilage sGAG 426 content in cross-sectional study designs. Of course, more research is needed, particularly 427 to assess reproducibility in OA patients before CTa could be applied in longitudinal 428 studies. Such a reproducibility study might also benefit from including more participants 429 and different delays between contrast administration and CT acquisition to assess if this 430 influences the correlation between CTa and cartilage composition in full thickness ROIs. 431
In addition, a depth-wise analysis to assess the effect of different concentrations of 432 cartilage composites throughout the extracellular matrix and across the cartilage layer 433 would be interesting, possibly include patellar cartilage, which is thicker and has been 434 shown to have a different composition than femoral and tibial cartilage (43) . Further 435 studies will also need to be performed to assess the capability of CTa to serve as a 436 predictive tool, for example for OA progression or clinical OA symptoms. Also, assessing 437 the capability of CTa to estimate cartilage sGAG and collagen content in fibrocartilage or 438 cartilage of other joints could be of interest to assess the influence of the differences in 439 cartilage composition on the diffusion of contrast agent into the cartilage. Nowadays, OA 440 19 is considered a whole joint disease in which not only cartilage, but also subchondral bone, 441 menisci and synovium play important roles in disease development and progression (44) . 442
The simultaneous analysis of cartilage and subchondral bone was also described 443 previously in in vitro studies using contrast-enhanced μCT (45, 46) . It would also be 444 worthwhile to assess the ability of CTa to evaluate cartilage and meniscus composition 445 within one examination. Simultaneous analysis of cartilage and meniscus composition has 446 recently been described for contrast-enhanced MRI (47, 48) and contrast-enhanced CT in 447 vitro (49, 50) . Finally, future research might assess the possibility of injecting the contrast 448 agent intravenously instead of intra-articularly to make the technique more patient 449 friendly. This dGEMRIC like approach will, however, be challenging because the 450 intra-articular contrast is also used for the purpose of cartilage segmentation. 451
Moreover, an intravenous approach requires a longer delay between contrast 452 administration and acquisition of the CT scan. 453
In conclusion, our study shows that when applied in vivo in human OA knees, 454 X-ray attenuation of CTa correlates well with sGAG content. Outcomes of CTa also 455 slightly correlate with cartilage collagen content. Since outcomes of CTa are mainly 456 sGAG dependent and despite the fact that further validation using hyaline cartilage of 457 other joint with different biochemical composition should be conducted, CTa may be 458 suitable as quantitative imaging biomarker to estimate cartilage sGAG content in 459 future clinical OA research. 460 461
